Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
ALNY Alnylam Pharmaceuticals, Inc. daily Stock Chart
ALNY [NASD]
Alnylam Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
financial highlights | statements
Index- P/E- EPS (ttm)-6.96 Insider Own0.30% Shs Outstand101.08M Perf Week-6.73%
Market Cap8.40B Forward P/E- EPS next Y-8.12 Insider Trans-14.76% Shs Float89.54M Perf Month14.59%
Income-693.10M PEG- EPS next Q-2.28 Inst Own90.60% Short Float7.09% Perf Quarter2.29%
Sales91.80M P/S91.52 EPS this Y-13.10% Inst Trans0.05% Short Ratio6.78 Perf Half Y-21.78%
Book/sh14.67 P/B5.67 EPS next Y-4.90% ROA-37.50% Target Price121.61 Perf Year-32.96%
Cash/sh12.24 P/C6.79 EPS next 5Y46.09% ROE-41.80% 52W Range60.27 - 153.99 Perf YTD14.00%
Dividend- P/FCF- EPS past 5Y-20.80% ROI-27.80% 52W High-46.02% Beta2.66
Dividend %- Quick Ratio11.00 Sales past 5Y6.10% Gross Margin99.90% 52W Low37.91% ATR4.60
Employees749 Current Ratio11.00 Sales Q/Q-87.70% Oper. Margin- RSI (14)58.66 Volatility4.73% 6.27%
OptionableYes Debt/Eq0.02 EPS Q/Q-81.80% Profit Margin- Rel Volume1.14 Prev Close80.68
ShortableYes LT Debt/Eq0.02 EarningsFeb 06 BMO Payout- Avg Volume935.58K Price83.12
Recom2.10 SMA209.55% SMA509.60% SMA200-9.20% Volume1,062,838 Change3.02%
Oct-01-18Initiated Cantor Fitzgerald Overweight $135
Aug-13-18Reiterated Stifel Buy $125 → $123
Aug-07-18Upgrade Stifel Hold → Buy $95 → $125
May-04-18Reiterated Stifel Hold $107 → $95
Mar-28-18Initiated Evercore ISI In-line
Mar-26-18Reiterated JMP Securities Mkt Outperform $169 → $207
Feb-16-18Reiterated B. Riley FBR, Inc. Buy $205 → $200
Jan-08-18Reiterated B. Riley FBR, Inc. Buy $220 → $205
Nov-09-17Upgrade JP Morgan Neutral → Overweight
Nov-08-17Reiterated Barclays Overweight $127 → $158
Nov-08-17Reiterated B. Riley FBR, Inc. Buy $240 → $220
Nov-03-17Reiterated Needham Buy $125 → $152
Nov-02-17Reiterated B. Riley FBR, Inc. Buy $150 → $240
Oct-30-17Initiated FBR & Co. Buy $150
Oct-02-17Upgrade Goldman Neutral → Buy
Sep-21-17Reiterated Needham Buy $85 → $125
Sep-15-17Initiated Instinet Reduce
Jun-22-17Resumed Jefferies Buy $102
May-15-17Reiterated Chardan Capital Markets Buy $95 → $110
Mar-30-17Initiated UBS Neutral $55
Jan-16-19 07:30AM  New Research Coverage Highlights Gentex, Tenneco, Mercury General, MGM Resorts International, ResMed, and Alnylam Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2019 GlobeNewswire
Jan-15-19 08:00AM  Pfizer Gets FDA's Priority Review for Rare Disease Candidate Zacks
Jan-14-19 09:13PM  Alnylam Pharmaceuticals Prices Public Offering of Common Stock Business Wire -5.72%
04:23PM  This Biotech Stock Plunged On Its Looming Rivalry With Pfizer Investor's Business Daily
04:04PM  Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock Business Wire
Jan-09-19 09:33AM  Biotech Stock Roundup: LOXO, CELG Gain, J.P. Morgan Healthcare Conference in Focus Zacks
Jan-08-19 04:52PM  3 Things Alnylam's Management Wants You to Know Motley Fool
09:54AM  Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks
Jan-07-19 09:58AM  Sales of Alnylam's first drug beat expectations in final quarter of 2018 American City Business Journals +8.75%
08:00AM  Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates Business Wire
Jan-02-19 03:48PM  Cannabis, Migraines, Gene-Silencing: FDA Approvals Hit High Note In 2018 Investor's Business Daily
Dec-28-18 07:00AM  Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-18 08:37AM  Alnylam (ALNY) Surges: Stock Moves 8.7% Higher Zacks
Dec-20-18 05:13PM  Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders Business Wire
Dec-18-18 09:29AM  RNAi Goes Big-Time in 2018 Motley Fool
08:55AM  Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved Benzinga
Dec-13-18 10:13AM  Top 10 Healthcare Stories of 2018 Motley Fool
07:00AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Array BioPharma ACCESSWIRE
Dec-10-18 07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
02:00AM  Alnylam Announces Settlement of Litigation with Silence Therapeutics Business Wire
Dec-08-18 12:44PM  Hedge Funds Are Dumping Alnylam Pharmaceuticals, Inc. (ALNY) Insider Monkey
Dec-07-18 06:11PM  [$$] Moderna IPO Marks Milestone for New Biotech Market The Wall Street Journal -6.71%
12:20PM  Modernas Rich IPO Valuation Raises the Stakes for Investors Bloomberg
Dec-06-18 08:15AM  Recent Analysis Shows Microsoft, Alnylam Pharmaceuticals, F5 Networks, Green Plains Partners LP, Itron, and Progress Software Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
07:00AM  Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day Business Wire
Nov-30-18 06:55AM  Today's Research Reports on Trending Tickers: Alnylam Pharmaceuticals and Sage Therapeutics ACCESSWIRE
Nov-29-18 05:30PM  Why Pfizer Could Lead These Two Biotech Stocks In Tackling Amyloidosis Investor's Business Daily
03:28PM  Alnylam CEO on drug prices: Has to be some type of reward... CNBC Videos
08:00AM  Alnylam to Webcast R&D Day Business Wire
Nov-27-18 03:41PM  Alnylam, Vir Begin Phase I/II Study on Hepatitis B Candidate Zacks
02:48PM  Why Alnylam Pharmaceuticals Incs (NASDAQ:ALNY) CEO Pay Matters To You Simply Wall St.
Nov-26-18 10:00AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) & Lead Plaintiff Deadline November 26, 2018 GlobeNewswire +6.83%
08:00AM  DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
07:00AM  Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218 Business Wire
Nov-25-18 06:07PM  DEADLINE TOMORROW: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
10:17AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TGTX, ALNY, CHGG, CWH and DY GlobeNewswire
09:00AM  ALNY NOV 26 DEADLINE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action GlobeNewswire
08:00AM  MONDAY DEADLINE: Kaskela Law LLC Announces Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ALNY GlobeNewswire
Nov-24-18 06:42PM  TUESDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
01:50PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. ALNY ACCESSWIRE
Nov-23-18 11:41AM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm ACCESSWIRE
10:30AM  DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
10:00AM  SHAREHOLDER ALERT: APOG TGTX ALNY ACHC JT HON DY ALGN RYAAY MGI: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
09:29AM  DEADLINE ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors With Losses Exceeding $100K of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) & Lead Plaintiff Deadline November 26, 2018 ACCESSWIRE
Nov-22-18 10:07AM  KESSLER TOPAZ MELTZER & CHECK, LLP:  Final Deadline Reminder for Alnylam Pharmaceuticals, Inc. Investors ALNY GlobeNewswire
Nov-21-18 04:35PM  CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) for Potential Breaches of Fiduciary Duties Business Wire
10:15AM  CLASS ACTION UPDATE for TGTX, ALNY and TRVN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
08:00AM  Alnylam to Webcast Presentations at Upcoming Investor Conferences Business Wire
Nov-20-18 09:43PM  Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Alnylam, MGT Capital, and Applied Optoelectronics and Encourages Investors to Contact the Firm GlobeNewswire
04:23PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ALNY, CHGG, CWH, DY and ALGN GlobeNewswire
02:30PM  SHAREHOLDER ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY ACCESSWIRE
12:10PM  6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
Nov-19-18 04:28PM  SHAREHOLDER ALERT: APOG ALNY ACHC COST TRVN SFIX ALGN AQUA TSRO MGI MDR: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
04:20PM  INVESTOR DEADLINE NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE
01:12PM  INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc. Business Wire
12:17PM  CLASS ACTION UPDATE for ABBV and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
11:47AM  7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
09:28AM  DEADLINE ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) & Lead Plaintiff Deadline November 26, 2018 ACCESSWIRE
Nov-18-18 10:05AM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ALNY, ACHC, TRVN, HTHT and SFIX GlobeNewswire
Nov-16-18 03:40PM  INVESTOR DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm ACCESSWIRE +5.46%
10:05AM  SHAREHOLDER ALERT: MCHP ALNY JT HTHT SFIX CWH OZK FIT RYAAY: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Nov-15-18 04:56PM  Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important November 26 Deadline in Class Action - ALNY PR Newswire +6.61%
03:55PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. to Contact the Firm ACCESSWIRE
03:35PM  Alnylam Pharmaceuticals Launches Onpattro Motley Fool
09:20AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) & Lead Plaintiff Deadline - November 26, 2018 ACCESSWIRE
Nov-14-18 07:55PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline ALNY ACCESSWIRE
03:05PM  ALERT: Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. ALNY ACCESSWIRE
02:25PM  IMPORTANT DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
Nov-13-18 03:09PM  CLASS ACTION UPDATE for MCHP, COCP and ALNY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
01:06PM  DEADLINE RAPIDLY APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
11:41AM  Edited Transcript of ALNY earnings conference call or presentation 7-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Nov-12-18 05:14PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MCHP, ALNY, CHGG, FIT and SONS GlobeNewswire -6.20%
04:15PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY ACCESSWIRE
12:50PM  Ionis Pharmaceuticals Collects Royalties -- and Spends It All Motley Fool
12:20PM  INVESTOR ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
09:24AM  Kessler Topaz Meltzer & Check, LLP - Important Deadline Reminder For Alnylam Pharmaceuticals, Inc. Investors GlobeNewswire
09:14AM  INVESTOR REMINDER ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Nov-11-18 12:00AM  SHAREHOLDER ALERT: ALNY ACHC JT TRVN HON DY AQUA SONS: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
Nov-09-18 09:15PM  SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
07:26PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline  ALNY GlobeNewswire
08:00AM  Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria Business Wire
Nov-08-18 01:00PM  INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:00PM  CLASS ACTION UPDATE for OPK, ALNY and CHGG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders GlobeNewswire
12:00PM  Pawar Law Group Announces a Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY ACCESSWIRE
09:39AM  Alnylam's (ALNY) Q3 Loss Narrower Than Expected, Sales Miss Zacks
Nov-07-18 07:33PM  Here's Why Alnylam Pharmaceuticals Crashed 11.9% on Wednesday Motley Fool -11.86%
05:35PM  SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY PR Newswire
03:15PM  FINAL DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
02:45PM  Alnylam Pharmaceuticals Inc (ALNY) Q3 2018 Earnings Conference Call Transcript Motley Fool
02:28PM  The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of OPK, MCHP, ALNY and CHGG GlobeNewswire
11:33AM  Alnylam shares take a hit amid sluggish sales of first drug American City Business Journals
10:15AM  Alnylam Pharmaceuticals (ALNY) Reports Q3 Loss, Misses Revenue Estimates Zacks
09:37AM  SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline - November 26, 2018 ACCESSWIRE
09:09AM  Alnylam: 3Q Earnings Snapshot Associated Press
08:00AM  Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity Business Wire
Nov-06-18 04:55PM  LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm GlobeNewswire
04:00PM  Alnylam to Webcast Presentations at Upcoming Investor Conferences Business Wire
03:59PM  SHAREHOLDER ALERT: OPK APOG ALNY MGTI CPB CHGG DY IGC FIT SYF: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines GlobeNewswire
03:10PM  DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm ACCESSWIRE
01:19PM  CLASS ACTION ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Significant Losses From Investment In Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) To Contact Brower Piven Before The Lead Plaintiff Deadline GlobeNewswire
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference (RNAi). Its pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, and hepatic infectious diseases. The company's clinical development programs include Patisiran, which is in Phase III clinical trial for the treatment of hereditary transthyretin-mediated amyloidosis; Givosiran that is in Phase III trial to treat acute hepatic porphyrias; Fitusiran, an investigational RNAi therapeutic that is in Phase II open-label extension and Phase III clinical trial for the treatment of hemophilia and rare bleeding disorders; and Inclisiran, which is in III clinical trial for hypercholesterolemia. Its clinical programs also include ALN-TTRsc02, an investigational RNAi therapeutic targeting TTR, which is in the Phase I clinical trial for the treatment of various forms of ATTR amyloidosis; Lumasiran (ALN-GO1) that is in Phase I/II clinical trial for the treatment of primary hyperoxaluria type 1; and Cemdisiran (ALN-CC5), which is in the Phase II clinical trial for the treatment of complement-mediated diseases. The company has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Monsanto Company; Takeda Pharmaceutical Company Limited; Ionis Pharmaceuticals, Inc; and Regeneron Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARAGANORE JOHNChief Executive OfficerNov 21Option Exercise21.3598,6362,105,879249,933Nov 26 04:11 PM
Greenstreet YvonneEVP, Chief Operating OfficerAug 30Sale120.002,500300,0001,916Sep 04 04:15 PM
MARAGANORE JOHNChief Executive OfficerJul 25Option Exercise21.3550,0001,067,500201,297Jul 27 04:07 PM
MARAGANORE JOHNChief Executive OfficerJul 25Sale105.3950,0005,269,457151,297Jul 27 04:07 PM
KEATING LAURIESVP, GC & SecretaryJun 20Option Exercise42.221,56365,99016,063Jun 22 04:20 PM
KEATING LAURIESVP, GC & SecretaryJun 20Sale105.041,563164,17814,500Jun 22 04:20 PM
CLARKE JOHN KDirectorMay 31Option Exercise27.2815,000409,20023,891Jun 04 04:25 PM
CLARKE JOHN KDirectorMay 31Sale100.3115,0001,504,6788,891Jun 04 04:25 PM
Greenstreet YvonneEVP, Chief Operating OfficerMar 26Option Exercise42.227,221304,8717,221Mar 28 04:39 PM
Greenstreet YvonneEVP, Chief Operating OfficerMar 26Sale136.547,221985,9580Mar 28 04:39 PM
KEATING LAURIESVP, GC & SecretaryMar 20Option Exercise42.221,56265,94816,062Mar 22 06:18 PM
KEATING LAURIESVP, GC & SecretaryMar 20Sale149.831,562234,03314,500Mar 22 06:18 PM
Vaishnaw AkshayPresident, R&DMar 14Option Exercise17.0388,5541,507,84299,769Mar 16 05:05 PM
Vaishnaw AkshayPresident, R&DMar 14Sale143.1088,55412,672,12611,215Mar 16 05:05 PM
Greene Barry EPresidentMar 14Sale143.1038,4605,503,73661,968Mar 16 05:05 PM
SCHIMMEL PAULDirectorMar 13Option Exercise49.2427,8231,369,92727,823Mar 14 07:39 PM
KEATING LAURIESVP, GC & SecretaryMar 13Option Exercise77.4010,000774,00024,500Mar 14 07:40 PM
Ausiello Dennis ADirectorMar 13Option Exercise59.8217,1171,023,94217,117Mar 14 07:40 PM
SHARP PHILIP ADirectorMar 13Option Exercise21.3515,000320,250155,795Mar 14 07:39 PM
SHARP PHILIP ADirectorMar 13Sale149.0015,0002,235,000140,795Mar 14 07:39 PM
Ausiello Dennis ADirectorMar 13Sale150.0017,1172,567,5500Mar 14 07:40 PM
KEATING LAURIESVP, GC & SecretaryMar 13Sale150.0010,0001,500,00014,500Mar 14 07:40 PM
SCHIMMEL PAULDirectorMar 13Sale150.0027,8234,173,4500Mar 14 07:39 PM
KEATING LAURIESVP, GC & SecretaryMar 12Option Exercise77.4010,000774,00024,500Mar 14 07:40 PM
KEATING LAURIESVP, GC & SecretaryMar 12Sale140.0010,0001,400,00014,500Mar 14 07:40 PM
SHARP PHILIP ADirectorMar 09Option Exercise27.2815,000409,200155,795Mar 13 05:22 PM
SHARP PHILIP ADirectorMar 09Sale129.0015,0001,935,000140,795Mar 13 05:22 PM
open in yahoo | open in reuters | open in google